Functional Endpoints and the New CNS Market Structure
Functional Endpoints, Persistence Economics, and Signal Interpretation in Modern Neuropsychiatry
1. Persistence Quietly Became the New Commercial Endpoint
Neuropsychiatry historically has been one of biotech’s least favored categories due to high placebo responses, weak biomarkers, subjective endpoints, elevated trial failure, and inconsistent FDA behavior. CNS was treated as a binary regulatory trade rather than a scalable chronic-care franchise comparable to cardiometabolic markets.
Biology and MOA targeting has now improved. More importantly, the commercialization paradigm has changed: terminal value in CNS is no longer driven by maximal symptom suppression, but by persistence economics that lock in predictable, durable revenue streams.
The first major signal of this model came from the launch trajectory of NBIX’s Ingrezza (and later TEVA’s Austedo). Wall Street initially treated Tardive Dyskinesia (TD) as a stagnant side-effect niche with limited commercial scalability and low effective patient penetration. Instead, Ingrezza rapidly evolved into a >$2.5B franchise despite a relatively modest actively treated patient base, forcing a reassessment of how CNS markets are commercialized.
Neurocrine demonstrated that CNS commercial bottlenecks often sit inside diagnosis intensity, prescribing workflows, treatment persistence, and outpatient manageability rather than efficacy alone. By deploying high-intensity physician education directly into community psychiatry, the company effectively uncovered a large underdiagnosed prevalent patient pool. Combined with visible functional benefit, once-daily simplicity, favorable tolerability, and LTC-channel penetration, TD evolved from a neglected side-effect market into a durable chronic-management franchise.
The next shift occurred inside schizophrenia. Psychiatry historically tolerated sedation, weight gain, EPS, and metabolic dysfunction in exchange for efficacy. That trade-off increasingly became commercially unacceptable.
ITCI’s Caplyta initially looked like another crowded schizophrenia entrant. Instead, tolerability, metabolic positioning, and bipolar depression expansion drove strong adoption and eventual acquisition. Similarly, ALKS’s Lybalvi demonstrated that even partial mitigation of olanzapine-associated weight gain carried meaningful commercial value inside a mature antipsychotic market.
Muscarinic agonists (KarXT/emraclidine) further de-risked the possibility that strong schizophrenia efficacy could coexist with materially cleaner long-term tolerability than historical D2-linked SGA burden (EPS, metabolic dysfunction, sedation, and poor persistence). Persistence may ultimately matter more commercially than incremental PANSS improvements. Medication non-adherence already drives >$50K excess annual healthcare costs per patient across chronic CNS markets, while relapse admission costs ~$18K.
Parallel workflow disruptions are validating this pattern across broader outpatient CNS markets. HRMY’s Wakix scaled despite scepticism against highly potent oxybates and generic stimulant-based wake-promoting drugs (WPA), with adoption driven more by chronic outpatient usability, non-scheduled positioning, oral convenience, and tolerability than maximal wake-promoting potency alone. Similarly, AXSM’s Auvelity scaled rapidly toward roughly ~$500M sales despite skepticism around MOA and crowded MDD competition, reinforcing how differentiated tolerability and ‘good enough’ efficacy can still scale in churn-heavy antidepressant markets.
This Is Not Another Zyprexa Cycle. Importantly, this is not a repeat of the Zyprexa/Abilify era (2000s). Earlier neuropsychiatry blockbusters succeeded inside a far less genericized market structure where branded oral antipsychotics faced limited payer resistance and weaker substitution pressure. Modern CNS markets operate under materially different commercial dynamics: hyper-genericized baseline therapy, aggressive step edits, Medicare Advantage cost scrutiny, and far faster generic erosion curves. Premium CNS assets now increasingly require demonstrable economic value capable of justifying reimbursement above entrenched generic standards of care.
Even FDA behavior began shifting under this framework. Approval of BIIB’s Leqembi signaled increasing willingness to accept slowing decline, functional preservation, earlier intervention, and biomarker-supported disease modification despite ongoing debate around amyloid biology.
Increasingly, CNS commercial value is being built around chronic usability, treatment persistence, functional maintenance, and reduction of outpatient friction rather than maximal symptom suppression alone.
2. CNS Is Fragmenting into Functional Markets
CNS markets fragmented into functional end-markets tied to independence, employability, behavioral stability, caregiver burden reduction, and hospitalization avoidance. Across neurology and psychiatry, commercial value now revolves around preservation of autonomy and outpatient stability vs. disease modification alone.
Alzheimer’s agitation is increasingly becoming an institutionalization-prevention market. Patients with significant agitation face a ~2–3x risk of institutionalization, while persistent agitation is associated with annual nursing home placement rates approaching ~25–30%. Transitioning from home-based care $110K–160K/year) creates a roughly ~$70K–100K incremental annual burden per patient. Agitation-control therapies are now being valued as institutionalization-delay assets rather than purely behavioral drugs.
Psychosis stabilization is similarly evolving into a hospitalization-avoidance market. Acute schizophrenia relapse admissions cost approximately ~$12K–18K per hospitalization, while roughly ~20–25% of patients are re-hospitalized within 30 days. Medication non-adherence contributes to nearly ~70% of relapses. The overall societal burden of schizophrenia is estimated near ~$367B annually, with indirect productivity and caregiver costs accounting for ~81% of total burden. Commercial focus shifted toward relapse prevention, adherence, and chronic outpatient stabilization.
TRD increasingly resembles a disability-reduction market rather than a pure antidepressant category. Relative to non-resistant MDD, TRD patients incur ~40% higher medical costs and ~3x productivity burdens. Effective augmentation strategies reduced mental health-related disability days by ~43%, positioning TRD therapies around restoration of workforce functionality rather than antidepressant efficacy alone.
Narcolepsy and orexin biology illustrate CNS commercialization moving toward functional normalization. Patients with narcolepsy face ~3–4x higher motor vehicle accident risk, while workplace productivity impairment averages ~35–45%. Emerging orexin agonists have demonstrated that roughly ~85% of patients can achieve normalized sleepiness scores (ESS ≤10), reframing the category from symptomatic wake-promotion toward restoration of wakefulness, occupational safety, and daytime functionality.
Adult ADHD now resembles a workforce-productivity market rather than a psychiatric category. The annual US societal burden is ~$105B–150B, driven primarily by indirect productivity loss. ADHD contributes to roughly ~120–140M lost workdays annually, while affected employees operate at only ~70–75% workplace efficiency. Commercial focus increasingly shifted toward therapies supporting chronic executive-function stability and workplace persistence.
Across CNS categories, the commercial endpoint shifted from symptom suppression toward preservation of functional autonomy. Agitation control delays institutionalization. Psychosis stabilization reduces hospitalization churn. Orexin restoration normalizes wakefulness and safety. ADHD therapies compete on productivity preservation. Functional impairment itself became measurable, reimbursable, and commercially scalable - it is now monetizable.
3. Modern CNS Investing Became a Signal Interpretation Problem
CNS investing increasingly faces a signal interpretation problem rather than a pure efficacy problem. Recently, biology, surrogate/novel endpoints, regulatory flexibility, and commercialization pathways aligned simultaneously, allowing CNS assets to become commercially relevant without requiring dramatic disease reversal.
The FDA and payers now accept slowing cognitive decline, functional stabilization, agitation reduction, relapse prevention, wakefulness normalization, caregiver benefit, and biomarker-supported progression delay as commercially meaningful endpoints.
Biology Reopened CNS
KarXT validated non-dopaminergic psychosis biology, while Takeda’s Oveporexton/TAK-861 demonstrated wakefulness normalization with ~85% of patients achieving ESS ≤10. Auvelity validated rapid NMDA-mediated neuropsychiatric modulation. These mechanisms now generate measurable downstream functional outcomes tied directly to commercialization.
The CNS Signal Stack Expanded
The CNS market now operates across an expanding “signal stack” where biomarkers, functional endpoints, imaging, and behavioral outcomes increasingly coexist inside both regulatory and commercial decision-making. FDA flexibility now incorporates pTau217/β-amyloid blood testing in AD, NfL reduction in ALS (Qalsody/Tofersen), amyloid PET-supported approvals such as Leqembi, agitation endpoints in dementia, relapse-reduction frameworks in schizophrenia, and wakefulness normalization metrics in narcolepsy.
CNS development now integrates:
plasma biomarkers (pTau217),
fluid biomarkers (tau/amyloid),
neurodegeneration markers (NfL),
imaging endpoints (amyloid PET),
behavioral endpoints (Auvelity agitation),
functional normalization metrics (ESS/MWT in orexin programs),
digital cognition and wearable-based tracking.
Regulatory Flexibility Expanded Faster Than Investor Frameworks
The FDA now accepts biomarker-supported accelerated approval pathways such as NfL reduction in ALS, while AD increasingly incorporates blood-based diagnostics and imaging-supported progression measures. Functional and behavioral endpoints also entered the commercial equation through Auvelity agitation, orexin wakefulness normalization, and relapse-reduction endpoints in psychosis.
Investors still lack a clear hierarchy for determining:
which biomarkers are durable,
which functional signals alter physician behavior,
which endpoints delay institutionalization,
and which signals ultimately translate into durable payer-supported adoption.
CNS asset development now produces mixed signal architectures. Xenon’s azetukalner demonstrated exploratory improvement in depressive and anhedonia symptoms despite missing its primary fMRI reward-circuitry endpoint, illustrating how CNS datasets can produce simultaneously positive and invalidating signals across behavioral, imaging, and functional endpoints.
The challenge today in CNS investing is no longer identifying signals. It is determining which signals matter commercially. Regulatory flexibility not only expanded the range of possible commercial outcomes but also widened interpretation dispersion across CNS assets.
Regulatory flexibility also increases the risk of signal over-interpretation. Controversial approvals such as Relyvrio (Amylyx) in ALS and prior amyloid-pathway debates demonstrated how surrogate endpoints, advocacy pressure, small datasets, and urgent unmet need can blur the distinction between biological signal and durable clinical value. CNS flexibility expanded commercial opportunity, but also amplified interpretation risk for regulators, payers, and investors.
Biomarker movement ≠ durable functional preservation.
Agitation reduction ≠ delayed institutionalization.
Wakefulness normalization ≠ payer adoption.
Relapse reduction ≠ longer treatment duration.
M&A and Capital Allocation Already Reflect the Shift
Bristol’s ~$14B acquisition of Karuna and AbbVie’s ~$8.7B acquisition of Cerevel signaled renewed pharma appetite for scalable CNS platforms spanning muscarinic psychiatry, schizophrenia, and neurodegeneration. Large pharma is re-entering CNS because functional outcomes, persistence economics, and regulatorily actionable endpoints now support commercially durable franchises beyond binary efficacy thresholds alone.
4. What the Market Still Underestimates
The next CNS winners may emerge from commercial architecture rather than disease labels alone. They are functional restoration platforms monetizing wakefulness, behavioral stability, executive function, cognition preservation, and chronic autonomy. Street still models CNS through disease prevalence and peak efficacy rather than diagnostic funnel expansion, treatment duration, and functional economics.
Functional Endpoints Expand TAM Faster Than Consensus Models
A. Agitation TAM may ultimately expand beyond portions of the AD DMT market (Leqembi/Kisunla) itself. Agitation drives institutionalization economics (~20% higher placement risk; ~$50K/year incremental LTC costs), pulling LTC facilities, geriatrics, behavioral management, and caregivers directly into the prescribing ecosystem.
Similarly, wakefulness normalization expands orexin TAM beyond narcolepsy into idiopathic hypersomnia, residual sleepiness in OSA, neurodegenerative fatigue, and broader cognitive-fatigue markets tied to workplace safety and productivity economics.
B. Adult ADHD is increasingly a workforce-productivity market rather than a psychiatric category. Untreated patients lose ~22 workdays/year and operate at roughly ~70% workplace efficiency, expanding commercial relevance into employer-sponsored insurance and workforce-function preservation. Functional markets may ultimately scale faster than traditional disease-defined CNS categories.
Workflow Compression May Matter More Than Incremental Efficacy
AD: Blood-based AD biomarkers may prove more commercially disruptive than modest efficacy deltas on cognitive scales. Historically, dementia diagnosis required roughly ~3.5 years from symptom onset. PCP-integrated pTau217 testing potentially compresses treatment eligibility timelines toward <6 months while reducing referral bottlenecks (~70-month projected specialist wait-times vs. ~13 months using BBM-based triage).
Blood biomarkers expand treatment duration, not just addressable patients. Plasma pTau217 approaches ~90% diagnostic accuracy in PCP settings vs. ~63% for traditional cognitive workflows and identifies pathology years before amyloid PET abnormality thresholds. Consensus still models AD primarily through symptomatic dementia prevalence rather than longitudinal diagnostic funnel expansion.
Parkinson’s may fragment into gait stability, falls prevention, cognitive fatigue, dyskinesia management, and continuous outpatient monitoring markets rather than episodic clinic-based motor assessment alone. PD already drives roughly ~$52B annual US economic burden, while >30% of patients are hospitalized annually. Emerging wearable-linked monitoring platforms have shown ~42% lower ER utilization, ~18% fewer specialist visits, and ~75% improvement in medication adherence through continuous gait, tremor, and speech tracking outside specialty clinics.
TG Therapeutics also demonstrated that workflow economics can drive meaningful differentiation even within mature efficacy-established CNS markets such as multiple sclerosis (MS). In a crowded anti-CD20 landscape, Briumvi leveraged a 1-hour maintenance infusion (vs. ~2–3.5 hours for Ocrevus) to reduce outpatient treatment friction, optimize infusion-center throughput, and lower administrative burden despite broadly similar efficacy to incumbent B-cell therapies.
CNS monetization is shifting from broad disease modification toward high-value functional niches:
agitation = LTC economics,
wakefulness = safety/productivity economics,
psychosis stabilization = hospitalization economics.
This fragmentation supports combination-therapy architectures over standalone “disease-modifying” assets. Future neurodegenerative management increasingly resembles: pathology-targeting backbone (Leqembi/Kisunla) + separate functional-maintenance assets targeting agitation, wakefulness, executive dysfunction, or psychosis.
Outcome-based reimbursement further reinforces this shift. It is easier to prove reduction in agitation-related hospitalization, relapse events, caregiver burden, or wakefulness impairment than demonstrating modest slowing of cognitive decline over multi-year timelines.
More Biomarkers ≠ More Clarity
Consensus still assumes more CNS biomarkers should reduce valuation uncertainty. The opposite may occur.
pTau217, NfL, GFAP, imaging, digital cognition, and gait metrics increasingly measure different pathological layers rather than a single “truth.” A drug hitting NfL (neurodegeneration) while missing pTau (tau pathology) creates biological success but commercial ambiguity. Biomarkers remain continuous, and interpretation-dependent rather than binary biomarker-positive/negative systems.
A 2026 review found only ~31% of digital biomarker publications used a clear definition, while >100 competing definitions remained across the literature. CNS biomarkers may reduce biological uncertainty while increasing commercial read-through uncertainty. Smaller datasets, functional unblinding, and subtype-specific biomarker divergence increasingly create valuation dispersion across superficially similar CNS assets. This widening interpretation dispersion may become one of the largest remaining alpha pools in specialist healthcare investing.
Conclusion: The next CNS winners may emerge from commercial architecture rather than binary efficacy alone: workflow expansion (blood-based AD diagnostics), persistence economics (long-acting ASOs, orexin durability), measurable functional endpoints (digital neurobehavioral tracking, wakefulness normalization), and combination architectures integrating pathology modification with functional maintenance.
Clinaptis Advisors | May 17, 2026